NEWS & ARCHIVE
ABOUT US
R & D
R & D
Contact Us
Links
 

Fostrap is designed to benefit patients who have high blood levels of phosphorus (hyperphosphataemia) as a result of kidney malfunction or renal failure, or who suffer from Chronic kidney disease (CKD) and may benefit from lowering phosphorus levels under medical advice. Hyperphosphataemia is a prime cause of vascular calcification and may lead to patients suffering additional clinical complications in the form of heart disease, bone disease and joint problems.

The novelty of Fostrap lies in its potential to start binding phosphorus in the saliva. It is being developed as complementary to current therapies so as to offer another pharmacological tool to doctors in their daily fight against phosphataemia.
The clinical development of Fostrap is already under way, with preliminary results published in the Journal of the American Society of Nephrology. Launch is expected in 2012.
 
Back to R & D menu
 
CURRENT NEWS :
© 2012 CM&D Pharma Limited. All rights reserved. Terms & Conditions.